Merck & Co. (NYSE:MRK) Archives - DRP Journal

Rising use of fentanyl

Merck & Co. (NYSE:MRK) Acquires Amptec To Enhance its mRNA manufacturing Capabilities With its PCR Tech

January 11, 2021January 11, 2021 DRP Staff 0 Comments Merck & Co., Merck & Co. (NYSE:MRK), NYSE:MRK

Merck & Co. (NYSE:MRK) has announced the acquisition of the leading mRNA contract development and manufacturing organization (CDM)), Amptec. The

Merck & Co. (NYSE:MRK)Signs $356 Million Deal for Supply of Its COVID-19 Treatment in the US

December 30, 2020December 30, 2020 DRP Staff 0 Comments COVID-19 therapies, COVID-19 treatment, drugmaker, Merck & Co, Merck & Co. (NYSE:MRK), MK-7110, molnupiravir, NYSE:MRK, OncoImmune, Ridgeback Biotherapy

Merck & Co. (NYSE:MRK) has signed a $356 million supply deal with the US government for the supply of 60,000